Literature DB >> 11397549

Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease.

E E Tuppo1, L J Forman, B W Spur, R E Chan-Ting, A Chopra, T A Cavalieri.   

Abstract

Free radical-induced oxidative damage may be involved in the neurodegenerative process associated with Alzheimer's disease (AD). 8-Isoprostaglandin F(2alpha) (iPF(2alpha)-III) is an isoprostane derived from free radical-induced non-enzymatic oxidation of arachidonic acid. It is formed in vivo and is an indicator of lipid peroxidation. Measurements were made of iPF(2alpha)-III in the urine of patients with mild to moderate dementia associated with probable AD and compared to those in the urine of non-demented subjects, who were similar in age and gender. 2,3-Dinor thromboxane B(2) (dinor TXB(2)), a urinary metabolite of TXB(2) was also measured, and served as an indicator of the enzymatic transformation of a product of arachidonic acid. Enzyme linked immunoassays were used to measure iPF(2alpha)-III and dinor TXB(2) in the urine. The concentration of iPF(2alpha)-III was significantly elevated in urine of patients assessed to have mild to moderate dementia as compared to non-demented patients. The concentration of urinary dinor TXB(2) was also significantly elevated in the patients with dementia and probable AD as compared to the non-demented subjects. There was considerable overlap of values obtained for demented and non-demented patients for iPF(2alpha)-III and dinor TXB(2), respectively. The observed elevation of iPF(2alpha)-III suggests that patients with mild to moderate dementia associated with probable AD are experiencing significant oxidative stress. This finding is consistent with current data suggesting that oxidative stress may be occurring in patients with dementia and probable AD. The increase of dinor TXB(2) may indicate that enzymatic processes related to the metabolism of arachidonic acid-derived products are also increased in demented patients with probable AD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397549     DOI: 10.1016/s0361-9230(01)00450-6

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  20 in total

Review 1.  Oxidative imbalance in Alzheimer's disease.

Authors:  Xiongwei Zhu; Hyoung-Gon Lee; Gemma Casadesus; Jesus Avila; Kelly Drew; George Perry; Mark A Smith
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

2.  Plasma F2-isoprostane level and cognitive function over eight years in non-demented older adults: Findings from the Health ABC Study.

Authors:  A J Fiocco; A M Kanaya; K M Lindquist; T B Harris; S Satterfield; E M Simonsick; L Kuller; C Rosano; K Yaffe
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2010-09-25       Impact factor: 4.006

Review 3.  Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease?

Authors:  Lap Ho; Weiping Qin; Breton S Stetka; Giulio M Pasinetti
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 4.  Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update.

Authors:  Melissa A Bradley-Whitman; Mark A Lovell
Journal:  Arch Toxicol       Date:  2015-04-18       Impact factor: 5.153

Review 5.  Fatty acid oxidation in the pathogenesis of Alzheimer's disease.

Authors:  Thomas J Montine; Jason D Morrow
Journal:  Am J Pathol       Date:  2005-05       Impact factor: 4.307

6.  CSF Biomarkers for Alzheimer's Disease Diagnosis.

Authors:  A Anoop; Pradeep K Singh; Reeba S Jacob; Samir K Maji
Journal:  Int J Alzheimers Dis       Date:  2010-06-23

Review 7.  Pathophysiological Roles of Cyclooxygenases and Prostaglandins in the Central Nervous System.

Authors:  Tatsurou Yagami; Hiromi Koma; Yasuhiro Yamamoto
Journal:  Mol Neurobiol       Date:  2015-09-02       Impact factor: 5.590

Review 8.  F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease.

Authors:  Thomas J Montine; Joseph Quinn; Jeffrey Kaye; Jason D Morrow
Journal:  J Mol Neurosci       Date:  2007-09       Impact factor: 3.444

Review 9.  Biomarkers of Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Anne M Fagan; David M Holtzman
Journal:  Neurobiol Dis       Date:  2008-10-28       Impact factor: 5.996

10.  Schizophrenia genomics and proteomics: are we any closer to biomarker discovery?

Authors:  Shaheen E Lakhan; Alon Kramer
Journal:  Behav Brain Funct       Date:  2009-01-07       Impact factor: 3.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.